Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (TORAVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00619268
Recruitment Status : Completed
First Posted : February 20, 2008
Last Update Posted : February 15, 2013
Information provided by (Responsible Party):
Centre Leon Berard

February 8, 2008
February 20, 2008
February 15, 2013
February 2008
February 2012   (Final data collection date for primary outcome measure)
progression-free rate [ Time Frame: at 48 weeks post-treatment ]
progression-free rate [ Time Frame: every 6 weeks during 48 weeks ]
Complete list of historical versions of study NCT00619268 on Archive Site
  • Objective response rate:efficacity [ Time Frame: Every 12 weeks during 48 weeks ]
  • Duration of response
  • Toxicity [ Time Frame: at week 2, week 5-6 and after every 5-6 weeks during 48 weeks ]
  • Quality of life [ Time Frame: at inclusion, month 6 and at 1 year ]
  • progression-free survival and overall survival
  • Objective response rate and the tumour regression rate :efficacity [ Time Frame: Every 6 weeks during 48 weeks ]
  • Duration of response [ Time Frame: every 6 weeks during 48 weeks and after every 3 months ]
  • Toxicity [ Time Frame: at week 2, week 5-6 and after every 5-6 weeks during 48 weeks ]
  • Quality of life [ Time Frame: at inclusion, month 6 and at 1 year ]
Not Provided
Not Provided
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.

The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.

This is a phase II, open label, randomized, parallel group, multicenter study evaluating first-line treatment of patients with metastatic renal cancer using a combination of Torisel® administered intravenously as 25 mg every week and Avastin® administered intravenously as 10 mg/kg every 2 weeks.

Two standard arms with either Sutent® (given orally as 50 mg once daily during 4 weeks, followed by 2 weeks off) or a combination of Avastin® (administered intravenously as 10 mg/kg every 2 weeks) and Interferon (IFN, administered subcutaneously as 9 MU three times a week) will be used to validate the results obtained in the experimental arm (randomization eliminates selection biases), and to assess Sutent® efficacy rate on a more representative population than in Motzer's trial (Motzer NEJM 2007).

The study is not designed to provide head-to-head comparisons between the experimental arm (Avastin® + Torisel®) and the two standard arms (Sutent® and IFN + Avastin®). Randomization will be used as a tool for allocating patients evenly into the 3 treatment arms to ensure proper balance of prognostic factors. If the progression-free rates observed in randomly assigned control patients are inconsistent with historical data, it may be a warning that the results observed for the experimental arm should be viewed with caution. Patients will be randomly assigned to either option in a 2:1:1 ratio (half less patients in the standard arms used only as historical comparators), and stratified according to inclusion center and performance status (ECOG PS 0 vs. 1 vs. 2).

In the absence of severe toxicity, treatment will be continued until documented progression of the disease (RECIST criteria). Toxicity will be evaluated throughout the treatment period and until disappearance or stabilization of the side effect(s). In case of progression, each investigator makes his/her own treatment decisions, provided that all anti-cancer treatments given to the patients within the frame of the study are reported, as well as their results.

Response rates will be assessed between weeks 11-12, 23-24, 35-36, 47-48 in the first year (corresponding to 2 cycles of Sutent®) and every 3 months afterwards until treatment stop, or until patient death or end of clinical data collection.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Metastatic Renal Cell Carcinoma
  • Drug: Temsirolimus
    25 mg once per week administered intravenously
    Other Name: Torisel®
  • Drug: Bevacizumab
    10 mg/kg * 1 time /2 weeks administered intravenously
    Other Name: Avastin®
  • Drug: Sunitinib
    50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
    Other Name: Sutent®
  • Drug: Interferon alpha-2a
    Administered subcutaneously as 9 MU three times per week
    Other Name: Roféron®
  • Experimental: A
    • Drug: Temsirolimus
    • Drug: Bevacizumab
  • Active Comparator: B
    Intervention: Drug: Sunitinib
  • Active Comparator: C
    • Drug: Bevacizumab
    • Drug: Interferon alpha-2a

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients>= 18 years of age;
  • Patients with histological or cytological evidence of metastatic renal cell carcinoma mostly of all type,except for papillary;
  • No prior systemic treatment (chemotherapy, immunotherapy, anti-angiogenic drugs, or treatment under evaluation) for metastatic renal cancer;
  • No brain metastases revealed by MRI or CT-scan within 28 days prior to randomization. Patients with a history of brain metastases treated by surgery +/- radiation therapy can be included if they have normal brain MRI;
  • E.C.O.G performance status =<2;
  • At least one measurable lesion using the RECIST criteria;
  • Blood tests and renal and liver functions in the normal range with, in the 7 days prior to study entry, blood or serum values as follows:

Hemoglobin > 8g/dl; Neutrophil count > 1500*10exp9/L; Platelets > 100*10exp9/L; Serum creatinine < 200µmol/L; Total Bilirubin < 1.5 times upper limit of normal; ALT and AST < 2.5 times upper limit of normal or < 5 ULN for patients with liver metastases, PT or INR < 1.5 times upper limit of normal in the absence of anticoagulant therapy;

  • Absence of proteinuria confirmed by urinary dipstick test
  • Fertile women must use effective means of contraception
  • Mandatory affiliation with a healthy security insurance
  • Signed written informed consent.

Exclusion Criteria:

  • Patient with pure papillary renal cell carcinoma
  • Prior systemic treatment for metastatic renal cancer
  • History of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization
  • Evidence of brain metastasis by computerized tomographic scan or MRI in the 28 days prior to randomization. Patients with history of brain metastases treated by exclusive brain therapy are not allowed to participate, even if brain MRI is normal
  • Significant cardiovascular disease or uncontrolled hypertension while receiving appropriate medication (>= 160 mm Hg systolic and/or >= 90 mm Hg diastolic)
  • Hepatic affection like chronic advanced hepatitis, liver cirrhosis or chronic hepatitis recently treated or in process of treatment by immunosuppressive agents, hepatitis auto-immune or history of auto-immune disease
  • Major surgical procedure, open biopsy, or serious non healing wound within 28 days prior to randomization
  • Uncontrolled hypercalcemia while receiving appropriate treatment
  • Uncontrolled hypercholesterolemia or hypertriglyceridemia
  • Patient under anti-vitamin K therapy
  • Patient under strong CYP3A4 inhibitors
  • Patient with severe neuropsychiatric disorder (or comitial crises)
  • Patient included in another clinical trial, except for supportive care trials
  • Pregnant or lactating women (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Centre Leon Berard
Centre Leon Berard
Not Provided
Principal Investigator: Sylvie NEGRIER, MD, PhD Centre Leon Berard
Principal Investigator: Bernard ESCUDIER, MD Gustave Roussy, Cancer Campus, Grand Paris
Centre Leon Berard
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP